Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 1, 2024Journal of the Endocrine SocietyOpen Access

8281 Continuous Low-Dose Etomidate Infusion For The Management Of Severe Hypercortisolism In Metastatic Adrenocortical Carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

AJAbid JamilNMNazar MohammadSNShyam Narayana

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jamil et al. (2024) studied this question.

synapsesocial.com/papers/68e56235e2b3180350effa2ehttps://doi.org/10.1210/jendso/bvae163.154
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1212: ETOMIDATE, KETOCONAZOLE, AND MITOTANE FOR CUSHING DISEASE DUE TO ADRENOCORTICAL CARCINOMA2026
  2. 2Normalization of Potassium Despite 11-Deoxycorticosterone Rise During Etomidate Therapy in Adrenocortical Carcinoma2026
  3. 3Etomidate Monotherapy for Perioperative Control of Hypercortisolism in a Mitotane-Intolerant Patient With Adrenocortical Carcinoma: A Case Report2026
  4. 47117 Cushings Conundrum: Taming The Hormone Hurricane2024
  5. 5A52-05 Use of Etomidate to Reduce Pressor Requirements in a Patient With Severe Ectopic Acth Syndrome Presenting With Shock2026